Skip to main content
. 2020 Apr 1;19(6):3859–3870. doi: 10.3892/ol.2020.11502

Figure 2.

Figure 2.

Kaplan-Meier survival analyses of first-line chemotherapy among patients with advanced non-small cell lung cancer. (A) Kaplan-Meier estimates of progression-free survival (9.1 months vs. 4.0 months) between patients with and without genetic alterations; (B) Kaplan-Meier estimates of overall survival (47.0 months vs. 47.0 months) between patients with and without genetic alterations. HR, hazard ratio.